RaltegravirIn Treatment-Naive Patients with HIV-1 Infection

被引：0
|
作者：
Jamie D. Croxtall
Lesley J. Scott
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2010年 / 70卷
关键词：
Tenofovir; Efavirenz; Virological Failure; Raltegravir; Integrase Mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Raltegravir, a first-in-class, oral HIV type-1 (HIV-1) integrase inhibitor, blocks the covalent integration of HIV-1 complementary DNA into the host genome.
引用
收藏
页码：631 / 642
页数：11
相关论文
共 50 条
  • [31] An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naive patients
    Putcharoen, Opass
    Kerr, Stephen J.
    Ruxrungtham, Kiat
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2013, 5 : 231 - 241
  • [32] Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients
    Birk, M
    Sönnerborg, A
    AIDS, 1998, 12 (18) : 2369 - 2375
  • [33] HIV-1 drug resistance patterns among treatment-naive and therapy-experienced patients in Poland
    Stanczak, G. P.
    Stanczak, J. J.
    Majchrzak, M. J.
    Burkacka, E.
    Wiercinska-Drapalo, A.
    Leszczyszyn-Pynka, M.
    Jablonowska, E.
    Malolepsza, E.
    Horban, A.
    HIV & AIDS REVIEW, 2007, 6 (01): : 32 - 36
  • [34] Management of HIV infection in treatment-naive patients: A review of the most current recommendations
    Boyd, Sarita D.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (11) : 991 - 1001
  • [35] Characteristics of Transmitted Drug-Resistant HIV-1 in Recently Infected Treatment-Naive Patients in Japan
    Hattori, Junko
    Shiino, Teiichiro
    Gatanaga, Hiroyuki
    Mori, Haruyo
    Minami, Rumi
    Uchida, Kazue
    Sadamasu, Kenji
    Kondo, Makiko
    Sugiura, Wataru
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (04) : 367 - 373
  • [36] Integrated Population Pharmacokinetic/Viral Dynamic Modelling of Lopinavir/Ritonavir in HIV-1 Treatment-Naive Patients
    Wang, Kun
    D'Argenio, David Z.
    Acosta, Edward P.
    Sheth, Anandi N.
    Delille, Cecile
    Lennox, Jeffrey L.
    Kerstner-Wood, Corenna
    Ofotokun, Ighovwerha
    CLINICAL PHARMACOKINETICS, 2014, 53 (04) : 361 - 371
  • [37] Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France
    Pialoux, Gilles
    Marcelin, Anne-Genevieve
    Cawston, Helene
    Guilmet, Caroline
    Finkielsztejn, Laurent
    Laurisse, Audrey
    Aubin, Celine
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (01) : 83 - 91
  • [38] HIV-1 Genetic Diversity and Drug Resistance Mutations Among Treatment-Naive Adult Patients in Suriname
    Wahid, Firoz Abdoel
    Sno, Rachel
    Darcissac, Edith
    Lavergne, Anne
    Adhin, Malti R.
    Lacoste, Vincent
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 (12) : 1223 - 1228
  • [39] Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial
    Nishijima, Takeshi
    Takano, Misao
    Ishisaka, Michiyo
    Komatsu, Hirokazu
    Gatanaga, Hiroyuki
    Kikuchi, Yoshimi
    Endo, Tomoyuki
    Horiba, Masahide
    Kaneda, Satoru
    Uchiumi, Hideki
    Koibuchi, Tomohiko
    Naito, Toshio
    Yoshida, Masaki
    Tachikawa, Natsuo
    Ueda, Mikio
    Yokomaku, Yoshiyuki
    Fujii, Teruhisa
    Higasa, Satoshi
    Takada, Kiyonori
    Yamamoto, Masahiro
    Matsushita, Shuzo
    Tateyama, Masao
    Tanabe, Yoshinari
    Mitsuya, Hiroaki
    Oka, Shinichi
    INTERNAL MEDICINE, 2013, 52 (07) : 735 - 744
  • [40] Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-Naive Patients with Advanced HIV-1 Infection in the HAART Era
    Mizushima, Daisuke
    Nishijima, Takeshi
    Gatanaga, Hiroyuki
    Tsukada, Kunihisa
    Teruya, Katsuji
    Kikuchi, Yoshimi
    Oka, Shinichi
    PLOS ONE, 2013, 8 (05):
12345